Applied Spectral Imaging (ASI) improves patient care through advanced image analysis.Founded in 1993, ASI is a global leader in the development of imaging and analysis platforms for pathology, cytogenetics, and life science research.ASIs GenASIs automated imaging platforms for pathology and genetic analysis provide advanced diagnostic aids for pathologists and cytogeneticists, with reproducible and reliable results. The GenASIs platform can be used with most brightfield or fluorescence microscope systems and supports manual and automatic scanning for a wide range of workflows and applications, to best suit the needs, size and budget of any lab.Our GenASIs HyperSpectral and HiSKY platform created the field of hyperspectral karyotyping (SKY) and is still recognized today as the field’s most advanced and productive platform.ASIs applications are US FDA cleared for BandView (karyotyping), FISHView, SpotScan (for CEP XY, UroVysion, ALK and HER2/neu FISH), and HiPath (for IHC Family: HER2, ER, PR and Ki67).ASI maintains comprehensive patent portfolios in the US, Europe, Japan and other countries.With thousands of Systems deployed worldwide, offices in the US, Europe and Asia, and a network of over 50 distributors, ASI also takes great pride in our outstanding record of service and support. We stand ready to answer your questions and assist you at all times.
Board and Advisors (0)
Funding Rounds (1)
M&A Events (1)
|Title||Date Announced||Amount ($)|
|ㅤApplied Spectral Imaging acquired by Danher for $30 million||September 2016||30,000,000|
|Investor Name||Investor Type||AUM ($)|
|ㅤGemini Israel Ventures||Venture Capital||700,000,000|
|ㅤYozma Group Asia||Venture Capital||0|
Research Publications (0)
AI Technology Stack
Computer vision algorithms for microscope based medical images, with segmentation algorithms for color images.